Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

Investigator Site 2, Berlin

Investigator Site 3, Berlin

Investigator Site 5, Hamburg

Investigator Site 6, Hamburg

Investigator Site 11, Münster

Investigator Site 10, Bad Bentheim

Investigator Site 9, Osnabrück

Investigator Site 8, Frankfurt am Main

Investigator Site 7, Darmstadt

Investigator Site 1, Augsburg

Investigator Site 12, Leipzig

Investigator Site 4, Dresden

Investigator Site 26, Krakow

Investigator Site 25, Krakow

Investigator Site 23, Wroclaw

Investigator Site 28, Warsaw

Investigator Site 27, Warsaw

Investigator Site 31, Iwonicz-Zdrój

Investigator Site 32, Katowice

Investigator Site 29, Ossy

Investigator Site 30, Gdansk

Investigator Site 13, Gdansk

Investigator Site 14, Katowice

Investigator Site 15, Kielce

Investigator Site 16, Lublin

Investigator Site 17, Poznan

Investigator Site 18, Rzeszów

Investigator Site 19, Szczecin

Investigator Site 20, Tarnów

Investigator Site 21, Warsaw

Investigator Site 22, Wroclaw

Investigator Site 24, Lodz